Zhifei biological heavyweight AC Hib vaccine is on the market after GMP certification

According to the information on CFDA website, the production workshops of two vaccine products, AC group meningococcal (combined) Haemophilus influenzae (combined) combined vaccine (hereinafter referred to as "AC Hib vaccine") and group a group C meningococcal polysaccharide combined vaccine of Zhifei biology, have passed the on-site inspection and audit and are in conformity with the new GMP regulations Among them, AC Hib vaccine is the company's heavyweight vaccine product, which has attracted market attention Zhifei said that the independent AC Hib vaccine will play a synergistic role with AC combined vaccine and Hib vaccine, fully meet the high-end market demand, further improve market share, strengthen the market position of the company, and enhance the market competitiveness and sustainable development ability The head of Zhifei biology once said that AC Hib triple vaccine is an upgraded product of Hib vaccine and AC group meningitis vaccine, which can prevent the related diseases caused by group A, group C meningococci and Haemophilus influenzae b at the same time, and can reduce the number of vaccinations The market price of the vaccine will be no less than 180 yuan / piece, and the market capacity is expected to be about 68 million pieces, with a high prospect The vaccine is a heavy-duty vaccine product that the company has high hopes for Public information shows that AC Hib vaccine is an upgraded product independently developed on the basis of existing Hib vaccine and AC group meningitis vaccine products The product completed the clinical experiment in April 2011, and applied for the production number in July 2011 The product is intended to be used in infants and children aged from 2 to 71 months It can prevent the related diseases caused by group A, group C meningococci and Haemophilus influenzae type B at the same time At present, only Zhifei biology is approved to produce the vaccine in China According to CFDA, the above two vaccine products are still in the publicity period, which is 10 working days, from August 29, 2014 to September 12, 2014.